1969P The SGLT2 inhibitor dapagliflozin enhanced anticancer activities and exerts cardioprotective effects against doxorubicin and trastuzumab toxicity through TLR4, MyD88, NF-kB signaling and NLRP3 inflammasome pathway

1969P The SGLT2 inhibitor dapagliflozin enhanced anticancer activities and exerts cardioprotective effects against doxorubicin and trastuzumab toxicity through TLR4, MyD88, NF-kB signaling and NLRP3 inflammasome pathway

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 31; p. S1106
Main Authors: Maurea, N., Quagliariello, V., Bonelli, A., Caronna, A., Grimaldi, I., Lombari, C., Conforti, G., Botti, G.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2020.08.1361